This is a Validated Antibody Database (VAD) review about mouse LAG 3, based on 45 published articles (read how Labome selects the articles), using LAG 3 antibody in all methods. It is aimed to help Labome visitors find the most suited LAG 3 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
LAG 3 synonym: CD223; LAG-3; Ly66

BioLegend
rat monoclonal (C9B7W)
  • flow cytometry; mouse; loading ...
BioLegend LAG 3 antibody (Biolegend, 125202) was used in flow cytometry on mouse samples . Cancer Cell (2021) ncbi
rat monoclonal (C9B7W)
  • flow cytometry; mouse; 1:100; loading ...; fig s22a
BioLegend LAG 3 antibody (Biolegend, C9B7W) was used in flow cytometry on mouse samples at 1:100 (fig s22a). Nat Commun (2021) ncbi
rat monoclonal (C9B7W)
  • flow cytometry; mouse; 1:200; loading ...
BioLegend LAG 3 antibody (Biolegend, C9B7W) was used in flow cytometry on mouse samples at 1:200. Nat Commun (2021) ncbi
rat monoclonal (C9B7W)
  • mass cytometry; mouse; loading ...
BioLegend LAG 3 antibody (BioLegend, 125202) was used in mass cytometry on mouse samples . Br J Cancer (2021) ncbi
rat monoclonal (C9B7W)
  • flow cytometry; mouse; loading ...; fig 6e
BioLegend LAG 3 antibody (Biolegend, 125210) was used in flow cytometry on mouse samples (fig 6e). elife (2020) ncbi
rat monoclonal (C9B7W)
  • flow cytometry; mouse; loading ...; fig 5e
BioLegend LAG 3 antibody (Biolegend, 125208) was used in flow cytometry on mouse samples (fig 5e). Cell (2019) ncbi
rat monoclonal (C9B7W)
  • flow cytometry; mouse; loading ...; fig s4f
BioLegend LAG 3 antibody (Biolegend, 125219) was used in flow cytometry on mouse samples (fig s4f). Cell (2019) ncbi
rat monoclonal (C9B7W)
  • flow cytometry; mouse; 1:100; fig 4a
BioLegend LAG 3 antibody (Biolegend, 125211) was used in flow cytometry on mouse samples at 1:100 (fig 4a). Nat Commun (2019) ncbi
rat monoclonal (C9B7W)
  • flow cytometry; mouse; 1:400; loading ...; fig ex4b
BioLegend LAG 3 antibody (BioLegend, C9B7W) was used in flow cytometry on mouse samples at 1:400 (fig ex4b). Nat Med (2019) ncbi
rat monoclonal (C9B7W)
  • flow cytometry; mouse; loading ...; fig 2d
BioLegend LAG 3 antibody (Biolegend, C9B7W) was used in flow cytometry on mouse samples (fig 2d). Science (2019) ncbi
rat monoclonal (C9B7W)
  • flow cytometry; mouse; loading ...; fig 2a
BioLegend LAG 3 antibody (Biolegend, 125210) was used in flow cytometry on mouse samples (fig 2a). Cell (2019) ncbi
rat monoclonal (C9B7W)
  • flow cytometry; mouse; loading ...; fig s2b, s2k
BioLegend LAG 3 antibody (BioLegend, C9B7W) was used in flow cytometry on mouse samples (fig s2b, s2k). Cell Rep (2018) ncbi
rat monoclonal (C9B7W)
  • flow cytometry; mouse; loading ...; fig 7a
BioLegend LAG 3 antibody (BioLegend, C9B7W) was used in flow cytometry on mouse samples (fig 7a). J Clin Invest (2018) ncbi
rat monoclonal (C9B7W)
  • flow cytometry; mouse; 1:200; loading ...; fig 3c
BioLegend LAG 3 antibody (BioLegend, C9B7W) was used in flow cytometry on mouse samples at 1:200 (fig 3c). J Clin Invest (2018) ncbi
rat monoclonal (C9B7W)
  • flow cytometry; mouse; loading ...; fig s3f
In order to investigate the use of red blood cells expressing disease-associated autoantigenas a means of inducing antigen-specific tolerance, BioLegend LAG 3 antibody (BioLegend, 125208) was used in flow cytometry on mouse samples (fig s3f). Proc Natl Acad Sci U S A (2017) ncbi
rat monoclonal (C9B7W)
In order to elucidate the interaction between tumor-associated and -infiltrating lymphocytes in ovarian cancer, BioLegend LAG 3 antibody (Biolegend, 125208) was used . Oncoimmunology (2017) ncbi
rat monoclonal (C9B7W)
  • flow cytometry; mouse; fig 3
In order to study the functions of WASp knock out natural killer cells, BioLegend LAG 3 antibody (Biolegend, C9B7W) was used in flow cytometry on mouse samples (fig 3). Sci Rep (2016) ncbi
rat monoclonal (C9B7W)
  • flow cytometry; human; loading ...; fig 6a
BioLegend LAG 3 antibody (BioLegend, C9B7W) was used in flow cytometry on human samples (fig 6a). J Clin Invest (2016) ncbi
rat monoclonal (C9B7W)
  • immunohistochemistry; mouse; 1:400; fig 5
BioLegend LAG 3 antibody (BioLegend, C9B7W) was used in immunohistochemistry on mouse samples at 1:400 (fig 5). PLoS ONE (2016) ncbi
Invitrogen
rat monoclonal (eBioC9B7W (C9B7W))
  • flow cytometry; mouse; 1:200; loading ...
Invitrogen LAG 3 antibody (eBioscience, 25-2231-80) was used in flow cytometry on mouse samples at 1:200. Nat Commun (2021) ncbi
rat monoclonal (eBioC9B7W (C9B7W))
  • flow cytometry; mouse; loading ...
Invitrogen LAG 3 antibody (eBiosciences, 25-2231-82) was used in flow cytometry on mouse samples . Cell (2021) ncbi
rat monoclonal (eBioC9B7W (C9B7W))
  • flow cytometry; mouse; loading ...
Invitrogen LAG 3 antibody (eBioscience, clone C9B7W) was used in flow cytometry on mouse samples . elife (2020) ncbi
rat monoclonal (eBioC9B7W (C9B7W))
  • flow cytometry; mouse; loading ...; fig 5f
Invitrogen LAG 3 antibody (eBioscience, eBioC9B7W) was used in flow cytometry on mouse samples (fig 5f). Cell (2020) ncbi
rat monoclonal (eBioC9B7W (C9B7W))
  • flow cytometry; mouse; loading ...; fig 6s1
Invitrogen LAG 3 antibody (eBioscience, C9B7W) was used in flow cytometry on mouse samples (fig 6s1). elife (2020) ncbi
rat monoclonal (eBioC9B7W (C9B7W))
  • flow cytometry; mouse; fig s5a
Invitrogen LAG 3 antibody (eBioscience, C9B7W) was used in flow cytometry on mouse samples (fig s5a). Nature (2019) ncbi
rat monoclonal (eBioC9B7W (C9B7W))
  • flow cytometry; mouse; loading ...; fig 7a
Invitrogen LAG 3 antibody (eBioscience, eBioC9B7W) was used in flow cytometry on mouse samples (fig 7a). Oncoimmunology (2019) ncbi
rat monoclonal (eBioC9B7W (C9B7W))
  • flow cytometry; mouse; loading ...; fig e4d
Invitrogen LAG 3 antibody (eBiosciences, eBioC9B7W) was used in flow cytometry on mouse samples (fig e4d). Nature (2018) ncbi
rat monoclonal (eBioC9B7W (C9B7W))
  • flow cytometry; mouse; fig 3c
In order to generate and characterize Treg-of-B cells, Invitrogen LAG 3 antibody (eBioscience, C9B7W) was used in flow cytometry on mouse samples (fig 3c). Sci Rep (2017) ncbi
rat monoclonal (eBioC9B7W (C9B7W))
  • flow cytometry; mouse; 1:300; loading ...; fig 6e
In order to test if oncolytic poxvirus treatment improves anti-PD-L1 immunotherapy, Invitrogen LAG 3 antibody (eBioscience, 48-2231-82) was used in flow cytometry on mouse samples at 1:300 (fig 6e). Nat Commun (2017) ncbi
rat monoclonal (eBioC9B7W (C9B7W))
  • flow cytometry; mouse; loading ...; fig 2e
Invitrogen LAG 3 antibody (eBioscience, eBioC9B7W) was used in flow cytometry on mouse samples (fig 2e). Blood (2017) ncbi
rat monoclonal (eBioC9B7W (C9B7W))
  • flow cytometry; mouse; fig 1
In order to investigate how organ-specific Btnl genes shape local T cell compartments, Invitrogen LAG 3 antibody (eBioscience, 46-2231-80) was used in flow cytometry on mouse samples (fig 1). Cell (2016) ncbi
rat monoclonal (eBioC9B7W (C9B7W))
  • flow cytometry; mouse; loading ...; fig 5f
In order to demonstrate that Blimp-1 controls CD4 T cell exhaustion, Invitrogen LAG 3 antibody (Affymetrix eBioscience, C9B7W) was used in flow cytometry on mouse samples (fig 5f). J Exp Med (2016) ncbi
rat monoclonal (eBioC9B7W (C9B7W))
  • flow cytometry; mouse; loading ...; fig 5
In order to report the effects of PD-L1 modulation of T cell function in graft-versus-host disease, Invitrogen LAG 3 antibody (eBioscience, C9B7W) was used in flow cytometry on mouse samples (fig 5). J Clin Invest (2016) ncbi
rat monoclonal (eBioC9B7W (C9B7W))
  • flow cytometry; mouse
In order to describe a method to expand antigen-specific regulatory T cells in vivo, Invitrogen LAG 3 antibody (eBioscience, C9B7W) was used in flow cytometry on mouse samples . Nature (2016) ncbi
rat monoclonal (eBioC9B7W (C9B7W))
  • flow cytometry; mouse; 1:100; fig s2
Invitrogen LAG 3 antibody (eBioscience, eBioC9B7W) was used in flow cytometry on mouse samples at 1:100 (fig s2). Nat Commun (2015) ncbi
rat monoclonal (eBioC9B7W (C9B7W))
  • western blot; mouse; 1:100; fig 5,6
Invitrogen LAG 3 antibody (eBioscience, C9B7W) was used in western blot on mouse samples at 1:100 (fig 5,6). Nat Commun (2015) ncbi
rat monoclonal (eBioC9B7W (C9B7W))
  • flow cytometry; mouse; fig s1
In order to test if blocking several checkpoint receptors boosts anti-tumor immunity in a low-dose, lymphodepleting whole body radiation model, Invitrogen LAG 3 antibody (eBioscience, C987W) was used in flow cytometry on mouse samples (fig s1). J Immunother Cancer (2015) ncbi
rat monoclonal (eBioC9B7W (C9B7W))
  • flow cytometry; human; fig 3
Invitrogen LAG 3 antibody (eBioscience, eBioC9B7W) was used in flow cytometry on human samples (fig 3). Cell Res (2015) ncbi
rat monoclonal (eBioC9B7W (C9B7W))
  • flow cytometry; mouse; 1:200
Invitrogen LAG 3 antibody (eBioscience, C9B7W) was used in flow cytometry on mouse samples at 1:200. Nat Commun (2014) ncbi
Bio X Cell
rat monoclonal (C9B7W)
  • other; mouse
Bio X Cell LAG 3 antibody (BioXcell, C9B7W) was used in other on mouse samples . Front Immunol (2020) ncbi
Abcam
domestic rabbit monoclonal (EPR20294-77)
  • immunohistochemistry - paraffin section; mouse; loading ...; fig 3e
Abcam LAG 3 antibody (Abcam, EPR20294-77) was used in immunohistochemistry - paraffin section on mouse samples (fig 3e). Biomolecules (2019) ncbi
BD Biosciences
rat monoclonal (C9B7W)
  • flow cytometry; mouse; loading ...
BD Biosciences LAG 3 antibody (BD Biosciences, C9B7W) was used in flow cytometry on mouse samples . Int J Mol Sci (2021) ncbi
rat monoclonal (C9B7W)
  • flow cytometry; mouse; loading ...; fig 2d
BD Biosciences LAG 3 antibody (BD Biosciences, C9B7W) was used in flow cytometry on mouse samples (fig 2d). Nature (2019) ncbi
rat monoclonal (C9B7W)
  • flow cytometry; mouse; 3:100; loading ...; fig 3a
BD Biosciences LAG 3 antibody (BD Biosciences, C9B7W) was used in flow cytometry on mouse samples at 3:100 (fig 3a). Proc Natl Acad Sci U S A (2016) ncbi
rat monoclonal (C9B7W)
  • flow cytometry; mouse; loading ...; fig s4e
In order to study T cell migration in inflammatory demyelinating lesions confined to optic nerves and spinal cord, BD Biosciences LAG 3 antibody (BD Pharmingen, C9B7W) was used in flow cytometry on mouse samples (fig s4e). Proc Natl Acad Sci U S A (2016) ncbi
Articles Reviewed
  1. Neumann S, Campbell K, Woodall M, Evans M, Clarkson A, Young S. Obesity Has a Systemic Effect on Immune Cells in Naïve and Cancer-Bearing Mice. Int J Mol Sci. 2021;22: pubmed publisher
  2. Hutton C, Heider F, Blanco Gómez A, Banyard A, Kononov A, Zhang X, et al. Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity. Cancer Cell. 2021;: pubmed publisher
  3. James O, Vandereyken M, Marchingo J, Singh F, Bray S, Wilson J, et al. IL-15 and PIM kinases direct the metabolic programming of intestinal intraepithelial lymphocytes. Nat Commun. 2021;12:4290 pubmed publisher
  4. Ho D, Tsui Y, Chan L, Sze K, Zhang X, Cheu J, et al. Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma. Nat Commun. 2021;12:3684 pubmed publisher
  5. Amoozgar Z, Kloepper J, Ren J, Tay R, Kazer S, Kiner E, et al. Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas. Nat Commun. 2021;12:2582 pubmed publisher
  6. Gangoso E, Southgate B, Bradley L, Rus S, Gálvez Cancino F, McGivern N, et al. Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion. Cell. 2021;184:2454-2470.e26 pubmed publisher
  7. Joseph R, Soundararajan R, Vasaikar S, Yang F, Allton K, Tian L, et al. CD8+ T cells inhibit metastasis and CXCL4 regulates its function. Br J Cancer. 2021;125:176-189 pubmed publisher
  8. Furtado R, Chorro L, Zimmerman N, Guillen E, Spaulding E, Chin S, et al. Blockade of LAG-3 in PD-L1-Deficient Mice Enhances Clearance of Blood Stage Malaria Independent of Humoral Responses. Front Immunol. 2020;11:576743 pubmed publisher
  9. Gryzik S, Hoang Y, Lischke T, Mohr E, Venzke M, Kadner I, et al. Identification of a super-functional Tfh-like subpopulation in murine lupus by pattern perception. elife. 2020;9: pubmed publisher
  10. Ruscetti M, Morris J, Mezzadra R, Russell J, Leibold J, Romesser P, et al. Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer. Cell. 2020;181:424-441.e21 pubmed publisher
  11. Hajaj E, Eisenberg G, Klein S, Frankenburg S, Merims S, Ben David I, et al. SLAMF6​ deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint. elife. 2020;9: pubmed publisher
  12. Canel M, Taggart D, Sims A, Lonergan D, Waizenegger I, Serrels A. T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity. elife. 2020;9: pubmed publisher
  13. Wei J, Long L, Zheng W, Dhungana Y, Lim S, Guy C, et al. Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy. Nature. 2019;576:471-476 pubmed publisher
  14. Lecocq Q, Zeven K, De Vlaeminck Y, Martens S, Massa S, Goyvaerts C, et al. Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use. Biomolecules. 2019;9: pubmed publisher
  15. Dong M, Wang G, Chow R, Ye L, Zhu L, Dai X, et al. Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells. Cell. 2019;178:1189-1204.e23 pubmed publisher
  16. Benci J, Johnson L, Choa R, Xu Y, Qiu J, Zhou Z, et al. Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. Cell. 2019;178:933-948.e14 pubmed publisher
  17. Leclerc M, Voilin E, Gros G, Corgnac S, de Montpreville V, Validire P, et al. Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1. Nat Commun. 2019;10:3345 pubmed publisher
  18. Khan O, Giles J, McDonald S, Manne S, Ngiow S, Patel K, et al. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature. 2019;: pubmed publisher
  19. Hammerich L, Marron T, Upadhyay R, Svensson Arvelund J, Dhainaut M, Hussein S, et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med. 2019;25:814-824 pubmed publisher
  20. Cox M, Duncan G, Lin G, Steinberg B, Yu L, Brenner D, et al. Choline acetyltransferase-expressing T cells are required to control chronic viral infection. Science. 2019;363:639-644 pubmed publisher
  21. Salerno F, Guislain A, Freen van Heeren J, Nicolet B, Young H, Wolkers M. Critical role of post-transcriptional regulation for IFN-γ in tumor-infiltrating T cells. Oncoimmunology. 2019;8:e1532762 pubmed publisher
  22. Wang J, Sanmamed M, Datar I, Su T, Ji L, Sun J, et al. Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3. Cell. 2019;176:334-347.e12 pubmed publisher
  23. Ding L, Kim H, Wang Q, Kearns M, Jiang T, Ohlson C, et al. PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. Cell Rep. 2018;25:2972-2980.e5 pubmed publisher
  24. Vendetti F, Karukonda P, Clump D, Teo T, Lalonde R, Nugent K, et al. ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation. J Clin Invest. 2018;128:3926-3940 pubmed publisher
  25. Du X, Wen J, Wang Y, Karmaus P, Khatamian A, Tan H, et al. Hippo/Mst signalling couples metabolic state and immune function of CD8α+ dendritic cells. Nature. 2018;558:141-145 pubmed publisher
  26. Hailemichael Y, Woods A, Fu T, He Q, Nielsen M, Hasan F, et al. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. J Clin Invest. 2018;128:1338-1354 pubmed publisher
  27. Chien C, Yu H, Chen S, Chiang B. Characterization of c-Maf+Foxp3- Regulatory T Cells Induced by Repeated Stimulation of Antigen-Presenting B Cells. Sci Rep. 2017;7:46348 pubmed publisher
  28. Liu Z, Ravindranathan R, Kalinski P, Guo Z, Bartlett D. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat Commun. 2017;8:14754 pubmed publisher
  29. Pishesha N, Bilate A, Wibowo M, Huang N, Li Z, Deshycka R, et al. Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease. Proc Natl Acad Sci U S A. 2017;114:3157-3162 pubmed publisher
  30. Huang R, Francois A, McGray A, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology. 2017;6:e1249561 pubmed publisher
  31. Asano T, Meguri Y, Yoshioka T, Kishi Y, Iwamoto M, Nakamura M, et al. PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. Blood. 2017;129:2186-2197 pubmed publisher
  32. Morita K, Okamura T, Inoue M, Komai T, Teruya S, Iwasaki Y, et al. Egr2 and Egr3 in regulatory T cells cooperatively control systemic autoimmunity through Ltbp3-mediated TGF-β3 production. Proc Natl Acad Sci U S A. 2016;113:E8131-E8140 pubmed
  33. Klotz L, Kuzmanov I, Hucke S, Gross C, Posevitz V, Dreykluft A, et al. B7-H1 shapes T-cell-mediated brain endothelial cell dysfunction and regional encephalitogenicity in spontaneous CNS autoimmunity. Proc Natl Acad Sci U S A. 2016;113:E6182-E6191 pubmed
  34. Di Marco Barros R, Roberts N, Dart R, Vantourout P, Jandke A, Nussbaumer O, et al. Epithelia Use Butyrophilin-like Molecules to Shape Organ-Specific γδ T Cell Compartments. Cell. 2016;167:203-218.e17 pubmed publisher
  35. Hwang S, Cobb D, Bhadra R, Youngblood B, Khan I. Blimp-1-mediated CD4 T cell exhaustion causes CD8 T cell dysfunction during chronic toxoplasmosis. J Exp Med. 2016;213:1799-818 pubmed publisher
  36. Kritikou J, Dahlberg C, Baptista M, Wagner A, Banerjee P, Gwalani L, et al. IL-2 in the tumor microenvironment is necessary for Wiskott-Aldrich syndrome protein deficient NK cells to respond to tumors in vivo. Sci Rep. 2016;6:30636 pubmed publisher
  37. Cherkassky L, Morello A, Villena Vargas J, Feng Y, Dimitrov D, Jones D, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126:3130-44 pubmed publisher
  38. Saha A, O Connor R, Thangavelu G, Lovitch S, Dandamudi D, Wilson C, et al. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. J Clin Invest. 2016;126:2642-60 pubmed publisher
  39. Foy S, Sennino B, dela Cruz T, Cote J, Gordon E, Kemp F, et al. Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice. PLoS ONE. 2016;11:e0150084 pubmed publisher
  40. Clemente Casares X, Blanco J, Ambalavanan P, Yamanouchi J, Singha S, Fandos C, et al. Expanding antigen-specific regulatory networks to treat autoimmunity. Nature. 2016;530:434-40 pubmed publisher
  41. Rouhani S, Eccles J, Riccardi P, Peske J, Tewalt E, Cohen J, et al. Roles of lymphatic endothelial cells expressing peripheral tissue antigens in CD4 T-cell tolerance induction. Nat Commun. 2015;6:6771 pubmed publisher
  42. Hsiao H, Hsu T, Liu W, Hsieh W, Chou T, Wu Y, et al. Deltex1 antagonizes HIF-1α and sustains the stability of regulatory T cells in vivo. Nat Commun. 2015;6:6353 pubmed publisher
  43. Jing W, Gershan J, Weber J, Tlomak D, McOlash L, Sabatos Peyton C, et al. Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. J Immunother Cancer. 2015;3:2 pubmed publisher
  44. Hannani D, Vétizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, et al. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res. 2015;25:208-24 pubmed publisher
  45. Burton B, Britton G, Fang H, Verhagen J, Smithers B, Sabatos Peyton C, et al. Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy. Nat Commun. 2014;5:4741 pubmed publisher